Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy | Cancer Cell International | Full Text
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. - Abstract - Europe PMC
Figure 1 | The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective | SpringerLink
Bortezomib
Bortezomib in the treatment of AL amyloidosis: targeted therapy? | Haematologica
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib: Cancer Cell
Kyprolis FOCUS Phase 3 Study for Multiple Myeloma | Cancer Biology
Suggested mechanism of the combination of IGF-I and bortezomib in... | Download Scientific Diagram
Proteasome inhibitors - ScienceDirect
Frontiers | The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia | Oncology
Kyprolis FOCUS Phase 3 Study for Multiple Myeloma | Cancer Biology
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy | Cancer Cell International | Full Text
IJMS | Free Full-Text | Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy | HTML
Bortezomib mechanism
Translational Research in the Development of Bortezomib: A Core Model - Ibis Sanchez-Serrano - Discovery Medicine
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies - Annals of Oncology
Advances in the Understanding of Mechanisms and Therapeutic Use of Bortezomib - Taskeen Mujtaba - Discovery Medicine
Resistance Mechanisms to Novel Therapies in Myeloma | IntechOpen
Suggested mechanism of the combination of IGF-I and bortezomib in... | Download Scientific Diagram
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib - Cancer Treatment Reviews
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma | Oncology
Bortezomib in mantle cell lymphoma | Future Oncology
A novel proteasome inhibitor NPI-0052 as an anticancer therapy | British Journal of Cancer
Bortezomib | Nature Reviews Drug Discovery
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
![PDF] Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1aa9b0038eb5d9d9aeed53d84df1efa5469c25bc/7-Figure3-1.png "PDF] Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma | Semantic Scholar")
PDF] Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma | Semantic Scholar
